CCR9 and acute lymphoblastic leukemia: The antitumor potential of 92R mAb was assessed in immunodeficient (Rag2−/−, BALB/c) mice, after subcutaneous injection of 2 × 106 CCR9+ cells from the human T-ALL cell line MOLT-4.